SLC12A3
ENSG00000070915
Target class
Transporter
Chromosome
16
Approved drugs
14
Clinical candidates (approved and in development)
14
- Approved drugs
- 14
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- No
- Target name
- SLC12A3
- Gene name
- Solute carrier family 12 member 3
- Gene symbol
- SLC12A3
- Protein name
- Solute carrier family 12 member 3 (Na-Cl cotransporter) (NCC) (Na-Cl symporter) (Thiazide-sensitive sodium-chloride cotransporter)
- NCCT
- NCC
- TSC
- Gene biotype
- Protein coding
- Gene family
- MicroRNA protein coding host genes|Solute carrier family 12
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 67.67
- Tissue specificity (Gini)
- 0.959
- Tissue specificity (tau)
- 0.992
- KEGG gene identifiers
- hsa:6559
- Protein interaction confidence
- 0.859526
- Protein interaction partners
- 19
- R-HSA-426117
- R-HSA-5619087
- End position
- 56915850
- Start position
- 56865207
- Chromosome
- 16
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Apical cell membrane
- Multi-pass membrane protein .
- PubMed 22009145
- PubMed 36370249
- PubMed 36351028
- PubMed 36792826
- Tissue specificity (tau)
- 0.992215
- Expression inequality (Gini)
- 0.958745
Expression in transcripts per million
- Kidney - Cortex
- 67.67
- Kidney - Medulla
- 24.94
- Spleen
- 0.75
- Cells - EBV-transformed lymphocytes
- 0.35
- Small Intestine - Terminal Ileum
- 0.18
Expression in transcripts per million
- Kidney - Cortex67.67
- Kidney - Medulla24.94
- Spleen0.75
- Cells - EBV-transformed lymphocytes0.35
- Small Intestine - Terminal Ileum0.18
- Testis0.17
- Stomach0.11
- Prostate0.11
- Pancreas0.09
- Brain - Hypothalamus0.09
- Brain - Substantia nigra0.07
- Lung0.05
- Brain - Caudate (basal ganglia)0.05
- Minor Salivary Gland0.05
- Brain - Nucleus accumbens (basal ganglia)0.05
- Pituitary0.05
- Fallopian Tube0.04
- Brain - Spinal cord (cervical c-1)0.04
- Ovary0.04
- Brain - Hippocampus0.04
- Brain - Cerebellum0.04
- Brain - Putamen (basal ganglia)0.04
- Thyroid0.04
- Bladder0.04
- Colon - Transverse0.04
And 29 more, listed on the interactive page.
- GO:0070294
- GO:1902476
- GO:0005886
- GO:0016020
- GO:0016324
- GO:0070062
- GO:0005515
- GO:0015378
- GO:0120283
Related records
Trials (500)
- 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
- A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
- A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
- A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
- A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
- A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients
- A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
- A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
- A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
- A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
- A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
- A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)
Drugs (14)
- Bendroflumethiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Benzthiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Chlorothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Chlorothiazide sodium Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Chlorthalidone Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Cyclothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Hydrochlorothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Hydroflumethiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Indapamide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Methyclothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Metolazone Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Polythiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Quinethazone Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Trichlormethiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor